Throughout the forecast period, the worldwide post-traumatic stress disorder treatment market is likely to be driven by an increasing number of inorganic initiatives such as product launches, collaborations, expansion, and partnerships to develop pharmaceuticals for the treatment of post-traumatic stress disorder. Throughout the projected period, the worldwide post-traumatic stress disorder treatment market is predicted to rise due to an increase in the number of product launches and collaboration between major industries participants in the treatment of PTSD. One of the fundamental constraints of the worldwide post-traumatic stress disorder. One of the significant limitations in the worldwide post-traumatic stress disorder treatment market is a lack of information about the pharmaceuticals used to treat post-traumatic stress disorder, such as Sertraline, Paroxetine, and others. Syncope, lightheadedness, diarrhoea, nausea, sweating, dizziness, xerostomia, disorientation, hallucinations, tremor, somnolence, impotency, lethargy, rhinitis, and female sexual dysfunction are the most common adverse effects of sertraline. Sertraline may also increase the risk of bleeding since it inhibits platelet aggregation.
According to Coherent Market Insights, Global Post-Traumatic Stress Disorder Treatment Market is estimated to be valued at US$ 1034.3 million in 2022 and is expected to witness a CAGR of 5.1% over the forecast period (2022 – 2030).
Market Players in the Post-Traumatic Stress Disorder Treatment Industry:
1. Jazz Pharmaceuticals plc.
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. It has licensing and collaboration agreements with Zymeworks Inc.; Sumitomo Pharma Co., Ltd; Werewolf Therapeutics, Inc.; Codiak BioSciences, Inc.; Ligand Pharmaceuticals Incorporated; XL-protein GmbH; and Redx Pharma plc. The company was incorporated in 2003 and is headquartered in Dublin, Ireland. In October 2020, Jazz Pharmaceuticals plc, a pharmaceutical company, and SpringWorks Therapeutics, Inc., a biotechnology company, announced that Jazz Pharmaceuticals Ireland Limited and SpringWorks entered into an asset purchase and exclusive license agreement under which Jazz had acquired SpringWorks' Fatty Acid Amide Hydrolase ("FAAH") inhibitor program including PF-04457845 in US$ 375 million.
2. Allergan PLC
It is Operator of a pharmaceutical company intended to focus on manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products. The company engages in medical aesthetics, eye care, central nervous system and gastroenterology and delivers innovative patient care. The company was founded in 1989, headquartered in Dublin.
3. Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceuticals is a pharmaceutical company that operates throughout the globe. The company was founded in 1989, headquartered in Maryland, U.S.
